Severe aplastic anemia (SAA) in developing countries may be treated with hematopoietic cell transplantation (HCT) from a matched family donor, but a sequential approach with immunosuppression first and an alternative donor HCT after failure, is rarely possible due to resource constraints.
In a pilot study we explored the feasibility of post-transplant cyclophosphamide (PTCY)-based haploidentical HCT in 10 patients (median 35 years, 6-46 years) with SAA without matched family donors. Written informed consent and ethical approval were obtained from all patients in accordance with the Declaration of Helsinki Principles. The conditioning protocol consisted of Fludarabine 30 mg/m 2 /day for 5 days and Cyclophosphamide 15 mg/kg/day for 2 days with Melphalan 120 mg/m 2 replacing 2 Gy total body irradiation (TBI; 1 due to lack of TBI facilities and the success of this protocol in our malignant cohort) along with horse antithymocyte globulin (ATG), at 15 mg/kg for 3 days from day − 8 to day − 6.
PTCY was administered as per the original protocol followed by cyclosporine (CSA) and mycophenolate (MMF). MMF and CSA were continued to days +35 and +180, respectively. This protocol was modified for the next five patients with the introduction of sirolimus on day − 7 with trough levels of 8-14 ng/mL on day 0 to be continued until 12 months. CSA levels were targeted at 200-300 ng/mL in the first cohort and 100-200 ng/mL in the modified protocol. This was stopped after day 100 if there was no GvHD. All patients received a peripheral blood stem cell (PBSC) graft.
The individual patient characteristics are described in Table 1 . All were heavily pre-transfused with a median of 35 (range 27-70) units of blood products and had a median time from diagnosis to HCT of 16 (range 6-46) months. Half of the patients had failed IST and 3/10 had active infection at the time of HCT. No regimenrelated toxicity was observed except in Patient 5, who developed a non-cardiogenic pulmonary edema following the second dose of ATG and recovered within 24 h but succumbed to acute respiratory distress syndrome (ARDS) within 72 h of PBSC infusion. She was not administered the scheduled dose of Melphalan. The median number of CD34+ cells in the graft were similar in both the groups. The neutrophils engrafted at a median of 13 days in both groups, but the platelet engraftment was delayed in the patients receiving sirolimus (18 days vs 13 days in non-sirolimus group, P = 0.02). Donor chimerism at day 30 was 100% in the nonsirolimus group and was between 88 and 100% (median 94%) in the sirolimus group. Only two patients developed GvHD, one grade 3 acute in the non-sirolimus group and one mild chronic in the sirolimus group. The overall incidence of infection remained low, with occurrence of CMV reactivation and invasive aspergillosis in patients 1 and 3, respectively, in the non-sirolimus group with none in the sirolimus group. In the sirolimus cohort, one patient (Patient 7) who had disseminated tuberculosis promptly responded to the therapy.
Regulatory T cells (TREGs; identified as percentage of CD4+ CD25 bright cells amongst CD3+T cells) were measured in the peripheral blood of the patients at median of 45 days, 100 days and 180 days post transplant. The patients receiving Sirolimus had a significantly better recovery of TREGs (2.6 ± 0.77%) compared to the first 3/5 patients (0.09 ± 0.13%; P = 0.001) at day 45. The TREGs continued to increase at days 90 and 180 in the Sirolimus group at 4.5 ± 0.86% and 5.4 ± 1.27%, respectively. No comparison was possible at a later time period due to early transplant-related mortality (TRM) in four of the five patients in the non-sirolimus group due to alloreactive complications within 150 days (Table 1) , despite prompt engraftment. All five patients in the sirolimus cohort are alive and well, one with mild chronic GvHD. There was no difference between the two groups in terms of age, gender, donor gender, donor type (maternal vs nonmaternal), degree of mismatch, CMV sero-status, NK ligand mismatched (NKLMM) donor, number of previous transfusions and graft composition. The overall survival was 60% (95% confidence interval (CI), 44.5-75.5) at a median follow-up of 2 years.
The factors that adversely impacted the survival were NKLMM donor and lack of sirolimus. Six patients received NKLMM graft, four in the non-sirolimus group and the last two patients in the sirolimus group (Patients 9 and 10). Although four of the six patients receiving a graft from a NKLMM donor died, all four patients grafted from non-NKLMM donors are alive. Irrespective of NKLMM donor, the 2-year survival was 100% in the patients receiving sirolimus, compared with 20% (95% CI, 2.1-37.9) in those not receiving the drug (log rank, P = 0.01).
Haploidentical HCT for SAA remains one of the major challenges in this field. Several small studies from Asian countries have reported on successful engraftment following either multiagent GvHD prophylaxis or T-cell depletion, with overall survival ranging from 65 to 90%. [2] [3] [4] [5] [6] Simultaneously, another group reported poor survival in eight heavily pre-treated patients with SAA, employing non-ablative conditioning and PTCY. 7 All patients in our study were heavily pre-transfused and were at high risk of graft failure as well as TRM. PTCY resulted in prompt and sustained engraftment in our cohort. Despite lack of severe GvHD and infections, four of the first five patients had early TRM. These were related to alloreactivity such as severe engraftment syndrome, hemophagocytic lymphohistiocytosis and ARDS. All four of these patients received a graft from NKLMM donors. NK alloreactivity based on KIR ligand mismatch has not been studied in SAA. It is speculative but possible, that alloreactive NK cells might eliminate host T cells and result in maturation of host dendritic cells 8, 9 augmenting alloreactivity of donor T cells.
We modified our protocol based on the following hypothesis: (a) Prompt engraftment, particularly in transplants from NKLMM donors indicated effective elimination of host rejection mechanisms. However, this was at the expense of early and fulminant donor alloreactivity that was not effectively thwarted by combination of PTCY, CSA and MMF as seen in the malignant diseases. (b) In addition, as the conditioning was largely nonmyeloablative, the induction of tolerance ought to be bidirectional. This is relevant based on the fact that TREGs are resistant to PTCY due to high expression of aldehyde dehydrogenase and might be instrumental in establishing bidirectional tolerance. 10 These considerations prompted us to introduce sirolimus in the protocol with the primary aim of reducing donor-derived alloreactivity and induce bidirectional tolerance. At the same time, we were concerned about the high incidence of thrombotic microangiopathy reported with the combination of CSA and sirolimus, and hence aimed for a lower CSA level. 11 Incidentally, a preclinical study by Fitzhugh et al. 12 published in 2013 (9 months after initiation of our clinical study) reported on synergism of sirolimus and PTCY in a mismatched murine model. In their experiments, the authors had reported on sustained mixed chimerism with PTCY and sirolimus.
The early recovery of TREGs in this small cohort might be indicative of a tolerance induction mechanism that could have resulted from synergism between PTCY and sirolimus, as demonstrated in the mismatched murine model. Our study has raised several important and interesting questions regarding haploidentical HCT in SAA. Larger studies are needed to address these issues.
